Eczema & Atopic Dermatitis: The Complete Clinical Guide

Eczema & Atopic Dermatitis: The Complete Clinical Guide

Eczema — or atopic dermatitis — is the most common inflammatory skin disease in the world, affecting up to 20% of children and 10% of adults globally. Yet for most sufferers, the clinical conversation begins and ends with topical steroids and moisturisers. What rarely happens is a systematic investigation of the underlying drivers: a dysregulated immune system, a compromised skin barrier, gut microbiome disruption, nutritional deficiencies, food sensitivities, liver burden, environmental triggers, and genetic susceptibility — all operating simultaneously on skin that is constitutionally primed to react.

This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional for diagnosis and treatment.

What Is Eczema? The Basics

Atopic dermatitis is a chronic, relapsing inflammatory skin condition characterised by intense itch (pruritus), skin barrier dysfunction, and immune dysregulation. The word "atopic" refers to a genetic tendency toward hypersensitivity — eczema sits within the "atopic triad" alongside asthma and allergic rhinitis, and having one significantly increases the risk of the others. This is not coincidence: all three share the same underlying immune imbalance.

Eczema is not simply dry skin. It is a systemic inflammatory disease with a visible skin manifestation. The itch-scratch cycle — where itching leads to scratching, which damages the barrier, which triggers more inflammation, which causes more itch — is the central self-perpetuating mechanism that makes eczema so difficult to break without addressing root causes.

The Genetics: Filaggrin, FLG Mutations, and the Broken Barrier

The most important genetic discovery in eczema research is the identification of loss-of-function mutations in the FLG gene, which encodes filaggrin — the master structural protein of the skin barrier. Filaggrin is essential for:

  • Cross-linking keratin filaments in the stratum corneum (the outermost skin layer) to form a tight, cohesive barrier
  • Breaking down into natural moisturising factors (NMF) — amino acids, urocanic acid, and pyrrolidone carboxylic acid — that maintain skin hydration
  • Maintaining the acidic pH of the skin surface (pH 4.5–5.5), which is critical for antimicrobial defence and enzyme regulation

FLG mutations are found in approximately 30% of European eczema patients and up to 50% of severe cases. But genetics is not destiny — FLG expression is also suppressed by Th2 cytokines (IL-4, IL-13), meaning that even people without FLG mutations can develop barrier dysfunction when the immune system is dysregulated. This creates a vicious cycle: immune activation suppresses filaggrin → barrier breaks down → allergens and microbes penetrate → immune activation increases.

Beyond filaggrin, eczema-associated genes include those encoding serine proteases (SPINK5/LEKTI), tight junction proteins (claudin-1), and immune regulators (IL-4Rα, IL-13, TSLP, OX40L) — confirming that eczema is simultaneously a barrier disease and an immune disease.

The Immune System in Eczema: Th2 Dominance and the Cytokine Storm

The healthy immune system maintains a dynamic balance between Th1 (cellular immunity, fighting viruses and intracellular pathogens) and Th2 (humoral immunity, fighting parasites and coordinating allergic responses). In atopic dermatitis, this balance is profoundly skewed toward Th2 dominance.

The Th2 Cascade

When allergens or irritants penetrate the broken skin barrier, keratinocytes release TSLP (thymic stromal lymphopoietin), IL-25, and IL-33 — the "alarmin" cytokines that activate dendritic cells and innate lymphoid cells (ILC2s). These drive naive T-cells toward the Th2 phenotype, which then produces the signature cytokines of eczema:

  • IL-4 — drives IgE class switching in B-cells (producing allergen-specific IgE), suppresses filaggrin expression, and promotes Th2 differentiation
  • IL-13 — the primary driver of barrier dysfunction; suppresses filaggrin, loricrin, and involucrin; promotes mucus production; the primary target of dupilumab
  • IL-31 — the "itch cytokine"; directly activates sensory neurons to produce pruritus; elevated in proportion to eczema severity
  • IL-5 — drives eosinophil production and survival; eosinophils are elevated in blood and skin in atopic dermatitis
  • IL-33 — amplifies the Th2 response and directly activates mast cells and ILC2s

IgE, Mast Cells, and Immediate Hypersensitivity

The Th2-driven IgE response sensitises mast cells in the skin. When allergens (food proteins, dust mite, pollen, pet dander) cross-link IgE on mast cell surfaces, mast cells degranulate — releasing histamine, tryptase, prostaglandins, and leukotrienes that drive immediate itch, vasodilation, and inflammation. This is the mechanism behind acute flares triggered by specific allergens.

Chronically elevated IgE is a hallmark of atopic dermatitis — total IgE levels often correlate with disease severity, though not all eczema is IgE-mediated (intrinsic eczema, more common in adults, has normal IgE with the same Th2 cytokine profile).

The Th1/Th17 Component in Chronic Eczema

In chronic, lichenified (thickened) eczema, the immune profile shifts — Th1 and Th17 cytokines (IFN-γ, IL-17, IL-22) become more prominent alongside the Th2 response. IL-22 in particular drives keratinocyte proliferation and barrier remodelling, contributing to the thickened, leathery skin of chronic eczema. This mixed Th2/Th22/Th17 profile in chronic disease explains why some patients respond less well to purely Th2-targeted biologics.

Regulatory T-Cells (Tregs) and Immune Tolerance

Healthy immune tolerance to environmental antigens depends on adequate regulatory T-cells (Tregs), which suppress excessive Th2 responses. In atopic dermatitis, Treg function is impaired — partly due to vitamin D deficiency (vitamin D is essential for Treg induction), partly due to gut microbiome dysbiosis (short-chain fatty acids from gut bacteria support Treg development), and partly due to the inflammatory cytokine environment itself. Restoring Treg function is one of the key mechanisms by which vitamin D, probiotics, and omega-3 fatty acids reduce eczema severity.

The Skin Barrier: Ceramides, Lipids, and the Acid Mantle

The stratum corneum functions like a brick wall — corneocytes (dead keratinocytes) are the bricks, and a lipid matrix of ceramides, cholesterol, and free fatty acids is the mortar. In eczema skin, this lipid matrix is profoundly abnormal:

  • Ceramide deficiency — total ceramide content is reduced by 30–50% in eczema skin; ceramides are the dominant lipid (50% of stratum corneum lipids) and are essential for water retention and barrier integrity
  • Altered fatty acid profile — reduced linoleic acid (omega-6) and increased oleic acid disrupts lamellar body structure and lipid organisation
  • Elevated serine protease activity — LEKTI deficiency (from SPINK5 mutations) allows kallikrein proteases to over-digest corneodesmosomes, causing premature desquamation and barrier disruption
  • Alkaline pH shift — eczema skin has elevated pH (6.0–7.0 vs normal 4.5–5.5), which activates serine proteases, impairs antimicrobial peptide function, and promotes Staphylococcus aureus colonisation

Staphylococcus aureus: The Skin Microbiome Disruptor

Over 90% of eczema patients are colonised with Staphylococcus aureus on affected skin, compared to ~5% of healthy controls. S. aureus is not merely a secondary coloniser — it is an active driver of eczema through multiple mechanisms: producing toxins (superantigens) that directly activate T-cells and mast cells; secreting proteases that degrade filaggrin and tight junction proteins; producing ceramidases that deplete skin ceramides; and inducing IL-4 and IL-13 production from keratinocytes. Reducing S. aureus burden — through barrier repair, antimicrobial peptide support, and targeted topical interventions — is a key therapeutic goal.

Topical Approaches: Barrier Repair, Zinc Oxide, and Tallow

The Case for Tallow-Based Barrier Creams

Beef tallow has emerged as one of the most physiologically compatible topical emollients for eczema-prone skin, and the science supports the clinical observation. Tallow's fatty acid profile — predominantly oleic acid (47%), palmitic acid (26%), stearic acid (14%), and linoleic acid — closely mirrors the lipid composition of human sebum and the stratum corneum. This structural similarity means tallow integrates into the skin's lipid matrix rather than simply sitting on the surface.

Critically, tallow contains fat-soluble vitamins A, D, E, and K in their natural, bioavailable forms. Vitamin A (retinol) directly supports keratinocyte differentiation and barrier protein synthesis. Vitamin D modulates local skin immune responses. Vitamin E is a potent lipid-phase antioxidant that protects barrier lipids from oxidative damage. These are the same nutrients that are deficient in eczema skin.

Grass-fed tallow also contains conjugated linoleic acid (CLA) and palmitoleic acid, which have demonstrated antimicrobial activity against S. aureus — directly addressing the microbiome disruption central to eczema pathophysiology. Unlike petroleum-based emollients (which occlude without integrating) or plant oils high in oleic acid (which can disrupt tight junctions), tallow provides genuine barrier restoration.

Zinc Oxide: The Multi-Mechanism Skin Protectant

Zinc oxide is one of the most clinically validated topical agents for eczema and inflammatory skin conditions, working through several simultaneous mechanisms. It provides a physical barrier that protects inflamed skin from environmental irritants, moisture loss, and microbial penetration. It has direct antimicrobial activity against S. aureus — reducing colonisation without promoting antibiotic resistance. It inhibits mast cell degranulation and histamine release, reducing acute itch and inflammation. It supports wound healing by providing zinc ions for metalloproteinase activity and keratinocyte migration. And it has mild astringent properties that help normalise the alkaline pH of eczema skin.

A tallow-zinc oxide combination cream provides both the lipid-phase barrier restoration of tallow and the antimicrobial, anti-inflammatory, and pH-normalising effects of zinc oxide — making it a physiologically rational first-line topical for eczema management.

Ceramide-Containing Emollients

Given the profound ceramide deficiency in eczema skin, topical ceramide replacement is a cornerstone of barrier repair. Ceramide-containing moisturisers have been shown in RCTs to reduce eczema severity, decrease steroid use, and improve quality of life. They work by directly replenishing the depleted lipid matrix, restoring lamellar body structure, and reducing transepidermal water loss (TEWL).

Pharmaceutical Treatments: From Steroids to Biologics

Topical Corticosteroids (TCS)

The first-line pharmaceutical treatment for eczema flares. They work by suppressing NF-κB-mediated inflammatory gene transcription, reducing cytokine production, and inhibiting immune cell recruitment to the skin. Highly effective for acute flares but associated with significant risks with prolonged use: skin atrophy, telangiectasia, striae, hypothalamic-pituitary-adrenal (HPA) axis suppression with potent steroids, and — critically — further suppression of filaggrin expression, worsening the underlying barrier defect. Topical steroid withdrawal (TSW) syndrome, characterised by rebound inflammation after cessation, is an increasingly recognised complication of long-term TCS use.

Topical Calcineurin Inhibitors (TCIs): Tacrolimus and Pimecrolimus

Non-steroidal anti-inflammatory topicals that inhibit calcineurin, blocking T-cell activation and cytokine production (particularly IL-2, IL-4, IL-5, IL-13, TNF-α). Effective for sensitive areas (face, eyelids, skin folds) where steroids cause most harm. Do not cause skin atrophy. Carry a black box warning regarding theoretical malignancy risk (not confirmed in long-term studies).

JAK Inhibitors: Ruxolitinib (Topical) and Upadacitinib, Abrocitinib (Oral)

The newest class of targeted small-molecule treatments. Janus kinase (JAK) inhibitors block the intracellular signalling pathways downstream of multiple cytokine receptors simultaneously — including IL-4Rα (JAK1), IL-13 (JAK1/TYK2), IL-31 (JAK1/JAK2), and TSLP (JAK1/JAK2). Oral JAK inhibitors (upadacitinib, abrocitinib) have shown remarkable efficacy in moderate-to-severe eczema, with rapid itch relief (often within days). Carry risks including increased infection susceptibility, thrombosis, and potential cardiovascular effects with long-term use.

Biologics: Dupilumab (Dupixent) and Beyond

Dupilumab is a monoclonal antibody targeting the IL-4Rα subunit shared by the IL-4 and IL-13 receptors — simultaneously blocking both cytokines. It is the most transformative treatment advance in eczema in decades, producing significant improvement in 60–70% of moderate-to-severe patients. It does not cause immunosuppression in the traditional sense (it targets specific Th2 pathways rather than broadly suppressing immunity). Common side effects include conjunctivitis and injection site reactions. Newer biologics targeting IL-13 alone (tralokinumab, lebrikizumab) and IL-31 (nemolizumab, for itch) are now available or in late-stage trials.

Antihistamines

Sedating antihistamines (chlorphenamine, promethazine) are commonly prescribed for itch but have limited evidence for eczema — histamine is only one of many itch mediators, and IL-31 (the dominant itch driver in eczema) does not act through H1 receptors. Non-sedating antihistamines have even less evidence. They may help with sleep disruption from itch but do not address the underlying inflammation.

The Gut-Skin Axis: How Your Microbiome Drives Your Skin

The gut-skin axis is one of the most compelling areas of eczema research. The gut microbiome — 38 trillion microorganisms — profoundly influences systemic immune tone, and its disruption (dysbiosis) is consistently associated with atopic dermatitis.

How Gut Dysbiosis Drives Eczema

Healthy gut bacteria produce short-chain fatty acids (SCFAs) — butyrate, propionate, and acetate — from fermenting dietary fibre. SCFAs are the primary fuel for colonocytes, maintain intestinal barrier integrity, and are essential for Treg induction in the gut-associated lymphoid tissue (GALT). Reduced SCFA production from dysbiosis impairs Treg function, allowing Th2 responses to go unchecked.

Gut dysbiosis also increases intestinal permeability ("leaky gut") — allowing bacterial lipopolysaccharide (LPS), food antigens, and microbial metabolites to translocate into the systemic circulation. This drives systemic low-grade inflammation and sensitises the immune system to food proteins that would otherwise be tolerated. Studies consistently show that infants who develop eczema have reduced gut microbial diversity, lower Lactobacillus and Bifidobacterium counts, and higher Clostridium and Staphylococcus in the first months of life — before eczema symptoms appear.

The landmark LEAP and EAT studies demonstrated that early oral exposure to food allergens (particularly peanut) in high-risk infants dramatically reduces sensitisation — confirming that gut immune education is critical for preventing atopic disease. This is the oral tolerance mechanism: food antigens presented to gut-associated immune cells in the context of a healthy microbiome induce Tregs rather than Th2 responses.

Probiotics for Eczema

The evidence for probiotics in eczema is strongest for prevention (maternal and infant supplementation reducing eczema incidence) and moderate for treatment (reducing severity in established disease). Lactobacillus rhamnosus GG, L. reuteri, and Bifidobacterium lactis have the most RCT evidence. Mechanisms include restoring microbial diversity, increasing SCFA production, supporting intestinal barrier integrity, and shifting immune tone toward Th1/Treg balance.

👉 Activated Probiotics Daily 30caps — practitioner-grade multi-strain probiotic; clinically relevant strains for immune modulation
👉 Probiotic 100B — high-potency 100 billion CFU; first-line for restoring gut diversity in dysbiosis
👉 Lifestream Probiotics 14 Strains 120vc — broad-spectrum 14-strain formula; supports microbiome diversity
👉 BePure Gut Regular — prebiotic and probiotic combination; supports SCFA production and gut barrier integrity

Food, Diet, and Eczema: IgE, IgG, Histamine, and Elimination

IgE-Mediated Food Allergy

True IgE-mediated food allergy (immediate hypersensitivity) is present in approximately 30–40% of children with moderate-to-severe eczema. The most common culprits are egg, cow's milk, wheat, soy, peanut, tree nuts, and fish. IgE-mediated reactions typically occur within minutes to 2 hours of ingestion and may trigger acute eczema flares alongside systemic symptoms (urticaria, vomiting, anaphylaxis). Diagnosis requires skin prick testing or specific IgE blood testing (RAST/ImmunoCAP) followed by supervised oral food challenge.

Non-IgE Food Sensitivity and IgG Reactions

Many eczema patients report food triggers without positive IgE testing. These delayed reactions (occurring 6–48 hours after ingestion) are thought to involve IgG-mediated immune complex formation, T-cell-mediated responses, and gut barrier dysfunction allowing food antigens to drive systemic inflammation. Common triggers include dairy, gluten, eggs, soy, corn, and high-histamine foods. IgG food testing is controversial in conventional medicine but is widely used in functional medicine as a guide for elimination trials.

Histamine Intolerance and DAO Deficiency

Histamine is present in many foods (fermented foods, aged cheese, wine, processed meats, spinach, tomatoes, avocado) and is also produced by gut bacteria. Normally, dietary histamine is broken down by diamine oxidase (DAO) in the gut epithelium. In eczema patients with gut dysbiosis, intestinal permeability, or nutritional deficiencies (DAO requires copper, vitamin B6, and vitamin C as cofactors), DAO activity is reduced — allowing dietary histamine to accumulate and trigger mast cell activation and skin inflammation.

A low-histamine diet trial (4–6 weeks) can be diagnostically and therapeutically valuable in eczema patients with suspected histamine intolerance, particularly those who flare after fermented foods, alcohol, or high-histamine meals.

The Anti-Inflammatory Diet for Eczema

Beyond specific triggers, the overall dietary pattern profoundly influences eczema through its effects on the gut microbiome, systemic inflammation, and nutritional status. Key principles include maximising dietary fibre diversity (30+ plant foods per week) to support microbial diversity and SCFA production; prioritising omega-3-rich foods (oily fish, flaxseed, walnuts) to shift the eicosanoid balance toward anti-inflammatory mediators; minimising ultra-processed foods, refined sugars, and seed oils (high in omega-6 linoleic acid) that drive arachidonic acid-mediated inflammation; and ensuring adequate protein for skin barrier protein synthesis.

The Liver Connection: Detoxification, Histamine, and Skin

The liver is the body's primary detoxification organ, and its function is intimately connected to skin health. In eczema, liver burden matters for several reasons.

Phase I and Phase II detoxification process endogenous metabolites (hormones, histamine, inflammatory mediators) and exogenous toxins (pesticides, food additives, environmental chemicals). When liver detoxification capacity is overwhelmed — by poor diet, alcohol, medications, or high toxic load — these compounds accumulate in the circulation and can drive systemic inflammation and skin reactions.

Histamine clearance is a critical liver function. The enzyme histamine N-methyltransferase (HNMT) is the primary intracellular histamine-degrading enzyme, and its activity depends on adequate methylation capacity (B12, folate, B6, magnesium). Impaired methylation — common in people with MTHFR variants — reduces histamine clearance and can contribute to histamine-driven eczema flares.

Bile production is essential for fat-soluble vitamin absorption (A, D, E, K) and for maintaining the gut microbiome composition. Impaired bile flow (from a sluggish liver or gallbladder) reduces absorption of the very nutrients most critical for skin barrier repair.

👉 Natroceutics Liposomal Milk Thistle 60caps — silymarin supports hepatocyte regeneration, phase I/II detoxification, and bile flow; liposomal delivery for superior absorption
👉 Natroceutics Milk Thistle 60caps — practitioner-grade silymarin standardised extract
👉 Designs For Health B Supreme — coenzymated B complex including methylfolate and methylcobalamin; supports methylation-dependent histamine clearance and phase II detoxification

Nutritional Medicine for Eczema: The Clinical Evidence

Vitamin D: The Immune Regulator

Vitamin D deficiency is significantly more prevalent in eczema patients than the general population, and serum 25(OH)D levels inversely correlate with eczema severity. Vitamin D's mechanisms in eczema are multiple and profound: it induces Treg differentiation (restoring Th1/Th2 balance), upregulates the production of antimicrobial peptides (cathelicidin/LL-37 and beta-defensins) that protect against S. aureus colonisation, directly stimulates filaggrin expression in keratinocytes, reduces IL-4 and IL-13 production from Th2 cells, and supports intestinal barrier integrity. Multiple RCTs show vitamin D supplementation reduces eczema severity scores (SCORAD, EASI) by 20–40%. NZ's latitude makes deficiency extremely common. Target 25(OH)D above 100 nmol/L.

👉 Vitamin D3 Liquid — flexible dosing for therapeutic titration; ideal for children and adults
👉 Vitamin D3 Vegan Liquid — plant-based D3 (lichen-sourced)
👉 Nordic Naturals Arctic-D Cod Liver Oil — D3 + omega-3 + natural vitamin A; triple benefit for eczema

Omega-3 Fatty Acids: Anti-Inflammatory and Barrier-Restorative

EPA and DHA address eczema through multiple pathways. They compete with arachidonic acid for COX and LOX enzymes, reducing the production of pro-inflammatory prostaglandin E2 and leukotriene B4 (a potent chemoattractant for eosinophils and neutrophils). They generate specialised pro-resolving mediators (SPMs — resolvins, protectins, maresins) that actively resolve inflammation rather than merely suppressing it. They incorporate into keratinocyte membranes, improving barrier function and reducing TEWL. And they modulate Th1/Th2 balance, reducing IgE production. Meta-analyses show omega-3 supplementation reduces eczema severity, particularly in children. The ratio of omega-3 to omega-6 in the diet is as important as absolute omega-3 intake — reducing seed oil consumption (omega-6) is as important as increasing omega-3.

👉 O.N.E. Omega — high-potency single daily dose; excellent EPA+DHA ratio; practitioner-grade
👉 BePure Three Fish Oil — NZ-made triple-strength fish oil
👉 Lifestream Vegan Omega-3 — algae-sourced DHA/EPA; ideal for plant-based patients and children

Zinc: The Skin Mineral

Zinc is essential for eczema management both topically and systemically. Internally, zinc is a cofactor for over 300 enzymes involved in immune regulation, skin barrier protein synthesis, and wound healing. It inhibits mast cell degranulation and histamine release, supports Th1 immune responses (counterbalancing Th2 dominance), is required for DAO enzyme activity (histamine degradation), and is essential for vitamin A metabolism (zinc is required for retinol-binding protein synthesis). Zinc deficiency is common in eczema patients and correlates with disease severity. Serum zinc below 12 μmol/L warrants supplementation.

👉 Zinc Citrate 25mg — highly bioavailable zinc citrate at a therapeutic dose
👉 Pure Encapsulations Zinc Citrate — practitioner-grade; hypoallergenic formulation ideal for sensitive patients
👉 Pure Encapsulations Zinc 30 — 30mg zinc for therapeutic dosing in deficiency

Histidine Deficiency: The Overlooked Amino Acid

Histidine is an essential amino acid with a uniquely direct relationship to eczema — one that is almost entirely overlooked in conventional dermatology. Its relevance operates through three distinct mechanisms.

First and most critically, histidine is the direct precursor to histamine. The enzyme histidine decarboxylase (HDC) converts histidine to histamine in mast cells, basophils, gut enterochromaffin-like cells, and gut bacteria. In eczema patients with gut dysbiosis, overgrowth of histamine-producing bacteria (including Lactobacillus reuteri, Morganella morganii, and Klebsiella pneumoniae) can dramatically increase histamine production from dietary histidine — contributing to the histamine load that drives mast cell activation and skin inflammation. This is the paradox of histidine: adequate dietary intake is essential for protein synthesis, yet excess histidine in the context of dysbiosis fuels the histamine cascade.

Second, histidine is a structural component of filaggrin itself. Filaggrin breakdown products include urocanic acid — formed from histidine via the enzyme histidase (HAL). Urocanic acid is a key component of the skin's natural moisturising factor (NMF) and plays a critical role in maintaining the acidic pH of the stratum corneum. In eczema patients with FLG mutations or Th2-mediated filaggrin suppression, reduced filaggrin breakdown means reduced urocanic acid production — contributing to the alkaline pH shift that promotes S. aureus colonisation and serine protease overactivation. Adequate histidine availability supports whatever residual filaggrin synthesis capacity remains.

Third, histidine has direct anti-inflammatory and antioxidant properties independent of its role as a histamine precursor. It is a component of carnosine (β-alanyl-L-histidine), a dipeptide with potent antioxidant, anti-glycation, and anti-inflammatory activity in skin tissue. Carnosine inhibits NF-κB activation, reduces lipid peroxidation in barrier membranes, and chelates transition metals that catalyse oxidative damage. Histidine also chelates copper and zinc ions, modulating the activity of metalloenzymes involved in skin repair and immune regulation.

Clinically, low plasma histidine has been documented in patients with chronic inflammatory conditions, and dietary histidine supplementation has shown anti-inflammatory effects in small clinical trials. Rich dietary sources include meat, poultry, fish, eggs, and dairy — making histidine deficiency more likely in restrictive or plant-based diets. In the context of eczema management, ensuring adequate dietary protein with diverse amino acid profiles (including histidine) is foundational, while simultaneously addressing gut dysbiosis to prevent excess histamine generation from histidine substrate.

Vitamin A: The Skin Differentiation Vitamin

Vitamin A (retinol) is essential for keratinocyte differentiation, barrier protein synthesis, and immune regulation. It directly supports filaggrin expression, promotes the production of antimicrobial peptides, and modulates T-cell responses toward immune tolerance. Vitamin A deficiency produces a clinical picture that overlaps significantly with eczema: dry, scaly skin, increased susceptibility to skin infections, and impaired barrier function. Fat-soluble vitamin A from animal sources (retinol) is directly usable; plant-source beta-carotene requires conversion that is impaired in many people (particularly those with BCO1 gene variants).

👉 NOW Vitamin A 10,000 IU — preformed retinol; directly bioavailable
👉 Solgar Cod Liver Oil 100 Sgels — natural source of vitamins A and D with omega-3; the ancestral eczema remedy

Quercetin: The Natural Mast Cell Stabiliser

Quercetin is a flavonoid with remarkable relevance to eczema pathophysiology. It stabilises mast cell membranes, inhibiting degranulation and histamine release — reducing the acute itch and inflammation of allergic flares. It inhibits NF-κB, reducing the production of IL-4, IL-5, IL-13, and TNF-α. It inhibits histidine decarboxylase (the enzyme that converts histidine to histamine), reducing endogenous histamine production. It has direct antioxidant activity, protecting barrier lipids from oxidative damage. And it inhibits phosphodiesterase, increasing intracellular cAMP in mast cells and basophils — a mechanism shared with some pharmaceutical anti-allergy drugs. Bioavailability is the critical variable; enhanced delivery forms are significantly more effective.

👉 Natroceutics Quercetin 60caps — enhanced bioavailability; NZ-made practitioner grade; first-line for mast cell stabilisation
👉 Quercetin 120c — high-dose quercetin for therapeutic use
👉 Solgar Quercetin Complex with Ester-C — quercetin combined with vitamin C for synergistic antihistamine and antioxidant effect

NAC (N-Acetyl Cysteine): Glutathione Precursor and Antioxidant

NAC is the rate-limiting precursor to glutathione — the body's master antioxidant and the primary defence against oxidative stress in the skin. Eczema skin has measurably reduced glutathione levels and elevated oxidative stress markers. NAC replenishes glutathione, reducing oxidative damage to barrier lipids and proteins. It also has direct anti-inflammatory effects: inhibiting NF-κB, reducing IL-4 and IL-13 production, and modulating mast cell activation. Additionally, NAC supports liver phase II detoxification (glutathione conjugation) and reduces histamine burden by supporting methylation pathways.

👉 Designs For Health NAC 120vc — practitioner-grade NAC; first-line for glutathione support in eczema
👉 Augmented NAC 90caps — enhanced NAC formula with additional cofactors

Curcumin: NF-κB Inhibitor and Th2 Modulator

Curcumin targets multiple eczema mechanisms simultaneously: inhibiting NF-κB to reduce the production of IL-4, IL-5, IL-13, and TSLP; suppressing mast cell activation and histamine release; activating Nrf2 to upregulate glutathione and antioxidant defences; inhibiting COX-2 and LOX to reduce prostaglandin and leukotriene production; and modulating the gut microbiome toward a less inflammatory composition. Bioavailability is critical — standard curcumin has poor oral absorption and enhanced delivery systems are essential.

👉 NatroCeutics Curcumin Complete 60caps — enhanced absorption matrix; NZ-made practitioner grade
👉 Solgar Full Spectrum Curcumin 90 Sgels — liposomal delivery for superior bioavailability

Vitamin C: Collagen Synthesis and Antihistamine

Vitamin C is essential for collagen synthesis (required for skin structural integrity), is a direct antioxidant in the aqueous phase of skin, and has clinically relevant antihistamine activity — it degrades histamine enzymatically and reduces histamine release from mast cells. It is also a cofactor for DAO (histamine-degrading enzyme) and supports phase II liver detoxification. Liposomal delivery dramatically improves bioavailability compared to standard ascorbic acid.

👉 Liposomal Vitamin C — high-absorption liposomal delivery; first-line for therapeutic vitamin C dosing
👉 Natroceutics Lipo Vitamin C Complete — practitioner-grade liposomal C with cofactors
👉 Coyne Biomax Liposomal Vitamin C — phospholipid-encapsulated for gut-friendly high-dose delivery

Magnesium: The Anti-Inflammatory Mineral

Magnesium deficiency is extremely common and has direct relevance to eczema: magnesium inhibits mast cell degranulation and histamine release, is required for DAO enzyme activity, supports cortisol regulation (chronic stress depletes magnesium and worsens eczema), and is essential for the methylation cycle (histamine clearance). Magnesium also supports sleep quality — disrupted sleep is both a consequence and a driver of eczema flares through its effects on cortisol and immune regulation.

👉 Magnesium Glycinate 180c — best-tolerated form; excellent bioavailability; first-line for daily use
👉 RN Labs Magnesium Glycinate 180c — practitioner-grade magnesium glycinate

Collagen: Skin Structural Support

Collagen peptides provide the amino acid building blocks (glycine, proline, hydroxyproline) for skin structural proteins and support the extracellular matrix that underpins barrier integrity. Bovine collagen with ceramides is particularly relevant for eczema — providing both structural amino acids and the ceramide precursors that are depleted in eczema skin.

👉 BePure Bovine Collagen & Ceramides — collagen peptides with ceramides; directly addresses the dual deficiency of structural protein and barrier lipids in eczema skin

Environmental Triggers: The External Drivers

Environmental factors interact with genetic susceptibility and immune dysregulation to trigger and perpetuate eczema flares. The most clinically significant include:

  • House dust mite (HDM) — the most common environmental allergen in eczema; HDM proteases (Der p 1, Der p 3) directly cleave tight junction proteins and activate PAR-2 receptors on keratinocytes, triggering TSLP release and Th2 activation. HDM reduction measures (allergen-proof mattress covers, regular washing at 60°C, HEPA filtration) can meaningfully reduce flare frequency
  • Detergents and soaps — sodium lauryl sulphate (SLS) and other surfactants disrupt the stratum corneum lipid matrix, raise skin pH, and activate keratinocyte inflammatory pathways. Fragrance chemicals are among the most common contact allergens in eczema. Switching to fragrance-free, pH-balanced cleansers is foundational
  • Hard water — high calcium and magnesium content in hard water raises skin pH and interacts with soap to form irritating calcium soaps on the skin surface. Epidemiological studies show a consistent association between hard water and eczema prevalence
  • Chlorine in tap water — chlorine is a potent oxidant that depletes skin antioxidants and disrupts the skin microbiome. Vitamin C shower filters neutralise chlorine and are a simple, low-cost intervention
  • Synthetic fabrics — polyester and nylon trap heat and moisture, promoting S. aureus growth and mechanical irritation. Natural fibres (cotton, bamboo, silk) are significantly better tolerated
  • Stress — psychological stress is one of the most potent eczema triggers, operating through cortisol-mediated suppression of barrier function (cortisol reduces ceramide synthesis and filaggrin expression), neuropeptide release (substance P from nerve endings activates mast cells), and direct immune dysregulation (stress shifts immune balance toward Th2)

The Stress-Cortisol-Skin Connection

The skin is a neuroendocrine organ with its own HPA axis equivalent — keratinocytes, mast cells, and sensory nerve endings all produce and respond to stress hormones and neuropeptides. Chronic psychological stress drives eczema through cortisol-mediated suppression of filaggrin and ceramide synthesis (directly worsening barrier function), substance P release from cutaneous nerve endings (activating mast cells and driving neurogenic inflammation), and systemic Th2 skewing. The itch-scratch cycle itself is a stress amplifier — sleep deprivation from nocturnal itch elevates cortisol, which worsens the barrier, which increases itch.

👉 Designs For Health TriGandha 60caps — practitioner-grade ashwagandha; reduces cortisol by up to 30% in RCTs; supports HPA axis resilience
👉 Solgar Ashwagandha Root Extract 60caps — KSM-66 standardised extract; well-studied for cortisol reduction and stress resilience

What to Investigate: A Comprehensive Eczema Workup

A thorough eczema investigation should include serum 25(OH)D (vitamin D), zinc (serum or RBC), full blood count with differential (eosinophil count), total IgE and specific IgE panel (food and environmental allergens), thyroid panel (TSH, free T3, free T4, antibodies — thyroid dysfunction can drive skin inflammation), B12 and folate (methylation status), homocysteine (methylation marker), CRP and ESR (systemic inflammation), fasting glucose and insulin (metabolic drivers of inflammation), DAO enzyme activity or histamine/methylhistamine ratio (histamine intolerance), plasma amino acid profile including histidine (to assess amino acid adequacy), comprehensive stool analysis (gut microbiome, intestinal permeability markers, secretory IgA), and DUTCH test (cortisol patterns and sex hormone metabolism).

A Practical Eczema Protocol

Based on the evidence above, a comprehensive nutritional and lifestyle protocol for eczema might include:

The Bottom Line

Eczema is not a skin disease. It is a systemic condition — a visible expression of immune dysregulation, barrier dysfunction, gut microbiome disruption, nutritional deficiency, liver burden, and environmental provocation — that happens to manifest on the skin. Treating only the skin with steroids and moisturisers addresses the symptom while leaving every underlying driver intact.

The good news: most of these drivers are modifiable. A systematic investigation followed by targeted nutritional, gut, immune, and lifestyle intervention — alongside appropriate pharmaceutical management when needed — can meaningfully reduce eczema severity, frequency of flares, and dependence on immunosuppressive medications in the majority of patients.

Our dispensary stocks practitioner-grade formulations selected for bioavailability and clinical relevance. Browse our Wellness Dispensary or contact our team for personalised guidance.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Eczema diagnosis and treatment should be managed by a qualified healthcare professional.

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.